Contrast Nephropathy Associated FFA

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

August 1, 2024

Study Completion Date

December 1, 2024

Conditions

Contrast-induced NephropathyAcute Kidney Injury

Interventions

DEVICE

use of florescein

Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.

Trial Locations (1)

Saglik Bilimleri University, Istanbul

All Listed Sponsors

lead

Saglik Bilimleri Universitesi

OTHER

NCT06418542 - Contrast Nephropathy Associated FFA | Biotech Hunter | Biotech Hunter